Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Guardant Health, Inc.
GH
NASDAQ·Healthcare·Medical - Diagnostics & Research·Mkt cap $22.6B
$168.66
▼ -1.24%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$40.35 - $172.61
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 240.3% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
6 reasons
- Market-leading liquid biopsy platform with extensive clinical validation and real-world evidence
- Proprietary clinical-genomic dataset of advanced cancer patients enabling superior analytics and insights
- Integrated ecosystem connecting diagnostics, data, software, and clinical trial matching
- Strong relationships with oncologists, biopharmaceutical companies, and healthcare systems
- Regulatory approvals including FDA breakthrough designations and companion diagnostic certifications
- Continuous innovation pipeline with early detection and treatment selection applications
Bear Case
2 risks
- Above-average volatility (beta 1.6).
- Growth premium of 0.0x vs Life Sciences Tools peers. Reasonable for this growth rate.
Growth
Moderate growth ahead
Expansion of liquid biopsy adoption in early-stage cancer detection and treatment monitoring
Value
Growth premium of 0.0x vs Life Sciences Tools peers. Reasonable for this growth rate.
Momentum
Hot
+82.0% over 3m
Quality
Excellent
High-growth business (40% revenue growth, 65% gross margin). Pre-profit but investing in growth.
Dividend
None
No dividend
Smart-money signal
Who's buying GH right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Apr 28, 2026
MAY 7, 2026
Reported EPS of -$0.85 vs -$0.47 consensus (-80.8% surprise). Revenue of $301.7M vs $279.2M expected (+8.1%).
EPS surprise · last 4Q
0 of 1 beats
Q2 26
-80.8%
Next: Apr 28, 2026
Revenue trend · last 8Q
—
—
+30%
+21%
+31%
+39%
+39%
+48%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$177.2M
$191.5M
$201.8M
$203.5M
$232.1M
$265.2M
$281.3M
$301.7M
Margins · last 8Q
Gross
—
Operating
—
Profit
-37.1%
Wall Street consensus
14 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
$155.00
▼ -8.1% vs $168.66
Latest: Bernstein · Jul 2, 2026
5 analysts covering